Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

C.S.E. Verbrugge, M.C.M. Al, Y.G. Assaraf, D. Niewerth, J. van Meerloo, J. Cloos, M.S. van der Veer, G.L. Scheffer, G.J. Peters, E.T. Chan, J.L. Anderl, C.J. Kirk, S. Zweegman, B.A.C. Dijkmans, W.F. Lems, R.J. Scheper, T.D. de Gruijl, G. Jansen

Research output: Contribution to journalArticleAcademicpeer-review

83 Downloads (Pure)
Original languageUndefined/Unknown
Article number2
JournalExperimental hematology & oncology
Publication statusPublished - 2013

Cite this